Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 22;9(3):e001657. doi: 10.1136/jitc-2020-001657

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Effects of regorafenib on adoptive transfer of antigen-specific cytotoxic T cells. (A) Adoptive transfer of antigen-specific, carboxyfluorescein succinimidyl ester (CFSE)-labeled CD8+ T cells into C57BL/6 mice-bearing gp33-overexpressed Hepa1-6 cells subcutaneously. The antitumor efficacy of antigen-specific CD8+ T cells adoptively transferred into mice-bearing gp33-overexpressed tumors was enhanced by regorafenib (5 mg/kg/day) (N=8). (B) Immunohistochemistry staining and quantification of tumor-infiltrating CD8+ T cells. Data were analyzed using 20 images (regions of interest, ROI)/ tumor, 4 tumors from 4 mice in each treatment group. (C) The transferred T cells in peripheral blood, spleen, and lymph nodes were measured by flow cytometry. *, p < 0.05; **, p < 0.01; ***, p <0.001.